SeaStar Medical (NASDAQ:ICU) Posts Quarterly Earnings Results, Beats Estimates By $0.17 EPS

SeaStar Medical (NASDAQ:ICU) posted its quarterly earnings data on Wednesday. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.17, FiscalAI reports. SeaStar Medical had a negative net margin of 1,551.08% and a negative return on equity of 414.50%. The company had revenue of $0.42 million for the quarter, compared to the consensus estimate of $0.22 million.

SeaStar Medical Trading Up 1.8%

NASDAQ:ICU traded up $0.04 during mid-day trading on Wednesday, hitting $2.28. The company’s stock had a trading volume of 76,902 shares, compared to its average volume of 102,127. The company has a market capitalization of $8.64 million, a price-to-earnings ratio of -0.14 and a beta of -1.04. SeaStar Medical has a fifty-two week low of $2.07 and a fifty-two week high of $25.70. The stock has a fifty day moving average of $2.47 and a 200-day moving average of $4.14.

Institutional Investors Weigh In On SeaStar Medical

Several large investors have recently modified their holdings of ICU. XTX Topco Ltd raised its holdings in shares of SeaStar Medical by 395.4% in the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after buying an additional 48,674 shares in the last quarter. Jane Street Group LLC acquired a new stake in SeaStar Medical in the 4th quarter valued at $30,000. Finally, Millennium Management LLC acquired a new stake in SeaStar Medical in the 3rd quarter valued at $102,000. 1.69% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Maxim Group set a $6.00 target price on SeaStar Medical in a research report on Thursday, February 12th. Wall Street Zen raised SeaStar Medical to a “hold” rating in a report on Saturday, January 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, SeaStar Medical currently has an average rating of “Sell” and a consensus price target of $6.00.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.